Premier Alternatives

FEMSelect

Surgical Devices · Newark, DE · Founded 2012 · Privately Held (backing)

Developer of medical devices designed to treat pelvic organ prolapse disease in women. FEMSelect is based in Newark, DE and was founded in 2012. It was valued at $17 million at its later-stage round in Sep 2022, the last priced event on record. It has raised $12.2 million across 1 recorded round; the latest was an accelerator round in Jan 2018.

PMV mark · valuation
$17.0M
Oct 2026
Priced at
its later-stage round
Sep 2022
Total raised
$12.2M
Last round
Accelerator/Incubator
Jan 2018

FEMSelect key facts

as of Oct 2026
  • Developer of medical devices designed to treat pelvic organ prolapse disease in women.
  • FEMSelect is valued at approximately $17.0M as of Oct 2026, set at its later-stage round, Sep 2022; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $12.2M across 1 recorded rounds; the latest was Accelerator/Incubator in Jan 2018.
  • Notable investors include Springboard Enterprises, Keiretsu Forum, Innovation Authority, New York Angels, Robin Hood Ventures — 21 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$17.0M

Valued at $17.0M at its later-stage round, Sep 2022. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of FEMSelect with a free account
  • ·The complete investor list: 21 names
  • ·Watch FEMSelect: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

FEMSelect funding rounds

1 rounds
Jan 2018Accelerator/Incubator—▮
Full funding history →

FEMSelect valuation

FEMSelect was valued at $17 million at its later-stage round in Sep 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has FEMSelect raised?

FEMSelect has raised $12.2 million in total; 1 of its rounds is on record. The most recent was an accelerator round in Jan 2018.

FEMSelect investors

21 investors are on record for FEMSelect, including Springboard Enterprises, Keiretsu Forum, Innovation Authority and New York Angels.

Comparable companies

Comparable surgical devices names by valuation on PrivateMarketView: Imperative Care ($1.6 billion), SpyGlass Pharma (NAS: SGP) ($511 million) and Eximis Surgical ($18.7 million).

About FEMSelect

Developer of medical devices designed to treat pelvic organ prolapse disease in women. The company's devices offer a minimally-invasive surgical system for suturing ligaments of the pelvic floor without overnight hospital stays and scars, enabling physicians to conduct surgery without dissection or mesh.

Industry
Surgical Devices
Sector
Healthcare
HQ
Newark, DE, United States
Founded
2012
Employees
9
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.